Board of Directors

Our Board of Directors comprises industry veterans who provide expert insights and guidance to AgeneBio.

Patrick G. LePore
Chairman of the Board

Patrick G. LePore has served as our Chairman of the Board since June 2014. He has more than 30 years of experience in the pharmaceutical industry, spanning both the private and public sectors with board and operational experience in each. Most recently he served as Chairman, CEO and President of Par Pharmaceuticals, Inc. where he guided the company to a sale to Texas Pacific Group for approximately $2 billion. Mr. LePore began his career with Hoffmann La Roche and then founded Boron LePore and Associates, a medical communications company, which he took public in 1997 and was eventually sold to Cardinal Health in 2002. He is a member of the board of directors of PharMerica (NYSE:PMC), Villanova University and is a past director of Esprit Pharmaceuticals and Douglas Labs. Mr. LePore was also a founder and director of Franklin Community Bank. A graduate of Villanova University, he holds an MBA from Farleigh Dickinson University.

Jerry McLaughlin
President and Chief Executive Officer

Jerry McLaughlin has served as our President and Chief Executive Officer June 2014. He has 24 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to joining AgeneBio, he served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. until the company was acquired by Teva Pharmaceuticals Industries Ltd. in 2014. Mr. McLaughlin served in a variety of commercial leadership roles at Merck from 1990 to 2001 and Endo Pharmaceuticals from 2001 to 2007. He holds a BA in Economics from Dickinson College and an MBA from Villanova University.

Floyd Bloom, MD

Floyd Bloom, MD, has served as a member of our Board of Directors since October 2012. Dr. Bloom has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health and The Salk Institute. He began his biomedical research career with investigations of the conduction properties of single isolated axons, and transitioned to single neuron pharmacology in the early applications of microiontophoresis. Dr. Bloom was among the first to study neurotransmitter systems at the anatomical, physiological and pharmacological levels beginning with the noradrenergic innervation of cerebellum and cerebral. He was one of the first neurobiologists to utilize modern molecular biological techniques to identify, functionally characterize, and map brain specific genes. Recognizing the value of computers in neuroscience, he pioneered their application to neuro-anatomic investigations and the development of neuro-anatomic databases. His work has found considerable applicability to many enigmatic disorders of the nervous system such as the addictive states, the dementias and the major psychoses. From 1995 to 2000, Dr. Bloom was Editor-in-Chief of SCIENCE. He is a Trustee of Washington University in St. Louis, a founder and Director of Alkermes, Inc., and a consultant to Elan Pharmaceuticals. He earned his MD from Washington University in St. Louis.

Charles Clarvit

Charles Clarvit has served as a member of our Board of Directors since December 2013. Mr. Clarvit is CEO of his family office Clarvit Capital. Prior to that, he was CEO of Vinci Partners US and a former Managing Director and Co-Head of BlackRock Alternative Advisors, the firm’s fund of funds platform. He joined BlackRock in 2007 following acquisition of the fund of funds business of Quellos Group, LLC. At Quellos he served as Principal and oversaw the Quellos Client Group. Previously, he was a Managing Director with CIBC Oppenheimer & Co., responsible for alternative investment strategies. He is also on the Johns Hopkins Center for Financial Economics Advisory Board and a Trustee on the Board of Johns Hopkins University. He earned a bachelor’s degree in Social and Behavioral Sciences with a concentration in Economics and Statistics from the Johns Hopkins University in 1978.

Michela Gallagher, PhD
Founder and Scientific Advisor

Michela Gallagher, PhD, founded AgeneBio in 2008 and  serves as a Scientific Advisor. Dr. Gallagher is the Krieger-Eisenhower Professor of Psychological and Brain Science and heads the Neurogenetics and Behavior Center at Johns Hopkins University. She is a Fellow of the American Psychological Association, the American Psychological Society and the American Association for the Advancement of Science. She has spent 20 years researching memory and learning as well as the neurobiology of aging, having published more than 250 peer-reviewed papers, and brings this expertise to the company as it seeks to advance discoveries to address amnestic mild cognitive impairment and Alzheimer’s disease. Dr. Gallagher is the 2014 recipient of the Society for Neuroscience, Mika Salpeter Lifetime Achievement Award and in 2010 received the American Psychological Association, D.O. Hebb Distinguished Scientific Contribution Award. She was also the recipient of a Senior Research Scientist Award from National Institute of Mental Health (1990-1999), a Freedom to Discover Award from the Bristol-Myers Foundation (2003-2008), and Senior Scientist Award from the Ellison Medical Foundation (2008-2012). She has served the on Boards of Scientific Counselors at the National Institute of Mental Health and the National Institute on Aging and currently serves on the Scientific Advisory Board of the Stanley Center at the Broad Institute. Prior to joining Johns Hopkins in 1997, Dr. Gallagher rose through the faculty ranks at University of North Carolina at Chapel Hill, where she was the Kenan Professor of Psychology. She earned her PhD in Physiological Psychology from University of Vermont.

Ronald M. Nordmann

Ronald M. Nordmann has served as a member of our Board of Directors since September 2013. Mr. Nordmann is a private investor and spent 23 years on Wall Street as a financial analyst, primarily with PaineWebber, Inc., and Oppenheimer & Co., Inc., focusing on the pharmaceutical and biotechnology industries. During his career on the Street, he participated in numerous investment banking transactions. Mr. Nordmann was a partner at Deerfield Management, a healthcare hedge fund. Since retiring in 2000, he devoted his time to corporate governance. Mr. Nordmann sat on the boards of directors of 10 public and private pharmaceutical companies in three countries. Mr. Nordmann is an Emeritus Trustee of Johns Hopkins and sits on the boards of several not-for-profit community organizations including the American Red Cross. He received an undergraduate degree from Johns Hopkins University and an MBA from Fairleigh Dickinson University.